Modality
mAb
MOA
CAR-T CD19
Target
PARP
Pathway
PI3K/AKT
EoENarcolepsy
Development Pipeline
Preclinical
Oct 2025
→ Dec 2030
PreclinicalCurrent
NCT06983193
2,731 pts·Narcolepsy
2025-10→2030-12·Completed
2,731 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-024.7y awayInterim· Narcolepsy
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2030-12-02 · 4.7y away
Narcolepsy
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06983193 | Preclinical | Narcolepsy | Completed | 2731 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP |